Abstract Background Since 1 September 2016, bedaquiline and delamanid have been
administered for the treatment of patients with multidrug-resistant/rifampicin-resistant …

Abstract Purpose The Korea Centers for Disease Control & Prevention has implemented a
review process for the approval of new drugs used to treat patients with multidrug-resistant …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

Background Multidrug-resistant tuberculosis (MDR-TB) represents a major public health
concern, with an ongoing need for new effective treatments. Bedaquiline is an oral …

Objectives The objective of this study was to evaluate the efficacy and safety of the
sequential use of bedaquiline (Bdq) and delamanid (Dlm) in patients with multidrug-resistant …

Abstract Background/Purpose (s) Bedaquiline and delamanid were recently approved for
multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of …

The introduction of two novel drugs, bedaquiline and delamanid, has given hope for better
and shorter treatments of drug-resistant tuberculosis. A systematic review was conducted to …

BACKGROUND: The World Health Organization recommends adding bedaquiline or
delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective …

Multidrug-resistant tuberculosis (MDR-TB), a major global health concern, requires long-
term treatment with multiple drugs, which can cause many side-effects [1]. Therefore, an …